menu search

GKOS / Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR

Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR
Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol. Read More
Posted: Sep 8 2022, 13:32
Author Name: Zacks Investment Research
Views: 103140

GKOS News  

Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 1, 2023

Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript

Glaukos Corporation (NYSE:GKOS ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Chris Lewis - Vice President of Inv more_horizontal

Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

By Zacks Investment Research
November 1, 2023

Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2023, it might be worth cons more_horizontal

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

By Zacks Investment Research
October 5, 2023

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results. more_horizontal

Compared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key Metrics

By Zacks Investment Research
August 2, 2023

Compared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key Metrics

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compar more_horizontal

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

By Zacks Investment Research
July 20, 2023

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results. more_horizontal

Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease

By Zacks Investment Research
July 19, 2023

Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease

Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detec more_horizontal

Glaukos: Revising To Buy On These 3 Catalytic Factors

By Seeking Alpha
June 16, 2023

Glaukos: Revising To Buy On These 3 Catalytic Factors

Glaukos Corporation has 3 catalysts to price change going forward. These involve the company's performance, growth, and potential future developments. more_horizontal

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

By Zacks Investment Research
May 19, 2023

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results. more_horizontal


Search within

Pages Search Results: